Show simple item record

dc.contributor.authorEinarsson, Einar J
dc.contributor.authorPetersen, Hannes
dc.contributor.authorWiebe, Thomas
dc.contributor.authorFransson, Per A
dc.contributor.authorGrenner, Jan
dc.contributor.authorMagnusson, Mås
dc.contributor.authorMoëll, Christer
dc.date.accessioned2011-03-11T09:34:40Z
dc.date.available2011-03-11T09:34:40Z
dc.date.issued2010-10
dc.date.submitted2011-03-11
dc.identifier.citationInt J Audiol. 2010, 49(10):765-71en
dc.identifier.issn1708-8186
dc.identifier.pmid20874050
dc.identifier.doi10.3109/14992027.2010.485595
dc.identifier.urihttp://hdl.handle.net/2336/124208
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractThe aim of this study was to investigate long-term development of hearing in subjects who had received platinum-based chemotherapy in childhood or adolescence. Another aim was to assess the self-reported hearing loss handicap and compare it to audiometric measurements. Medical records from individuals diagnosed with childhood cancer and treated with platinum-based chemotherapy between 1985 and 2000 at the University Hospital in Lund Sweden were reviewed retrospectively. Fifteen subjects, who fulfilled the eligibility criteria set for the study, underwent a thorough audiometric evaluation. The results show that the hearing loss, in subjects with ototoxicity had increased after the end of treatment, to include also the lower frequencies. The largest deterioration in hearing thresholds, up to 55 dB HL, was found at frequencies above 2 kHz. The findings also reveal that the subjects have a considerably greater hearing loss handicap and disability than would be expected from the results of the audiometric evaluations. The conclusion of this study is that children and adolescence treated with platinum-based chemotherapy should have regular audiometric follow-up examinations, also many years after the end of treatment. Furthermore, assessments of self-reported hearing disability should be made during and after chemotherapy.
dc.language.isoenen
dc.publisherInforma Healthcareen
dc.relation.urlhttp://dx.doi.org/10.3109/14992027.2010.485595en
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAntineoplastic Agentsen
dc.subject.meshAudiometry, Pure-Toneen
dc.subject.meshAuditory Thresholden
dc.subject.meshCisplatinen
dc.subject.meshDisabled Personsen
dc.subject.meshDose-Response Relationship, Drugen
dc.subject.meshFemaleen
dc.subject.meshFollow-Up Studiesen
dc.subject.meshHearing Lossen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMedical Recordsen
dc.subject.meshRetrospective Studiesen
dc.subject.meshSeverity of Illness Indexen
dc.subject.meshSwedenen
dc.subject.meshYoung Adulten
dc.titleLong term hearing degeneration after platinum-based chemotherapy in childhooden
dc.typeArticleen
dc.contributor.departmentDepartment of Otorhinolaryngology, Head and Neck Surgery, Lund University, Lund, Sweden. einar-jon.einarsson@med.lu.seen
dc.identifier.journalInternational journal of audiologyen
html.description.abstractThe aim of this study was to investigate long-term development of hearing in subjects who had received platinum-based chemotherapy in childhood or adolescence. Another aim was to assess the self-reported hearing loss handicap and compare it to audiometric measurements. Medical records from individuals diagnosed with childhood cancer and treated with platinum-based chemotherapy between 1985 and 2000 at the University Hospital in Lund Sweden were reviewed retrospectively. Fifteen subjects, who fulfilled the eligibility criteria set for the study, underwent a thorough audiometric evaluation. The results show that the hearing loss, in subjects with ototoxicity had increased after the end of treatment, to include also the lower frequencies. The largest deterioration in hearing thresholds, up to 55 dB HL, was found at frequencies above 2 kHz. The findings also reveal that the subjects have a considerably greater hearing loss handicap and disability than would be expected from the results of the audiometric evaluations. The conclusion of this study is that children and adolescence treated with platinum-based chemotherapy should have regular audiometric follow-up examinations, also many years after the end of treatment. Furthermore, assessments of self-reported hearing disability should be made during and after chemotherapy.


This item appears in the following Collection(s)

Show simple item record